Secondary stroke prevention

Nature Reviews Neurology

Volumn 6, Issue 9, 2010, Pages 477-486

  Spence, J David ^a  

^a Stroke Prevention and Atherosclerosis Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMFEBUTAMONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CLOPIDOGREL; CYANOCOBALAMIN; DABIGATRAN; DIPYRIDAMOLE; EPLERENONE; EZETIMIBE; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; PREDNISONE; PYRIDOXINE; RIVAROXABAN; SPIRONOLACTONE; VARENICLINE; VITAMIN B GROUP; WARFARIN;

ALDOSTERONE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CAROTID ARTERY OBSTRUCTION; CAROTID ARTERY STENTING; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPEPSIA; EXERCISE; GIANT CELL ARTERITIS; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIDDLE SYNDROME; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDITERRANEAN DIET; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OBESITY; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SMOKING CESSATION; TOBACCO DEPENDENCE; TRANSIENT ISCHEMIC ATTACK; WEIGHT CONTROL;

ANIMALS; DIET, MEDITERRANEAN; HUMANS; HYPERTENSION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION; SMOKING CESSATION; STROKE;

EID: 77956343501     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.114     Document Type: Review

References (117)

1. Laupacis, A., Sackett, D. L. & Roberts, R. S. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 318, 1728-1734 (1988).
2. Lloyd-Jones, D. et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121, e46-e215 (2010).
3. Hackam, D. G. & Spence, J. D. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 38, 1881-1885 (2007).
4. Lewis, M., Trypuc, J., Lindsay, P., OCallaghan, C. & Dishaw, A. Has Ontarios Stroke System really made a difference? Healthc. Q. 9, 50-59 (2006).
5. Adams, R. J. et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39, 1647-1652 (2008).
6. Johnston, S. C., Gress, D. R., Browner, W. S. & Sidney, S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284, 2901-2906 (2000).
7. Chandratheva, A., Mehta, Z., Geraghty, O. C., Marquardt, L. & Rothwell, P. M. Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology 72, 1941-1947 (2009).
8. Rothwell, P. M. et al. effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (eXPReSS study): a prospective population-based sequential comparison. Lancet 370, 1432-1442 (2007).
9. Tsivgoulis, G. et al. Multicenter external validation of the ABCD2 score in triaging TIA patients. Neurology 74, 1351-1357 (2010).
10. Amarenco, P. et al. Does ABCD2 score below 4 allow more time to evaluate patients with a transient ischemic attack? Stroke 40, 3091-3095 (2009).
11. Giles, M. F. & Rothwell, P. M. Stroke: using the ABCD system to evaluate transient ischemic attack. Nat. Rev. Neurol. 5, 470-471 (2009).
12. Giles, M. F. & Rothwell, P. M. Systematic review and pooled analysis of published and unpublished validations of the ABCD and ABCD2 transient ischemic attack risk scores. Stroke 41, 667-673 (2010).
13. Chiuve, S. e. et al. Primary prevention of stroke by healthy lifestyle. Circulation 118, 947-954 (2008).
14. Spence, J. D. How to Prevent Your Stroke (Vanderbilt University Press, Nashville, 2006).
15. Bonita, R., Duncan, J., Truelsen, R., Jackson, R. T. & Beaglehole, R. Passive smoking as well as active smoking increases the risk of acute stroke. Tob. Control 8, 156-160 (1999).
16. Aronow, W. S. Effect of passive smoking on angina pectoris. N. Engl. J. Med. 299, 21-24 (1978).
17. Reid, R. D. et al. Smoking cessation for hospitalized smokers: an evaluation of the "Ottawa Model". Nicotine Tob. Res. 12, 11-18 (2010).
18. Pipe, A. Tobacco addiction and smoking cessation therapies. Presented at the 20th Annual R. W. Gunton Symposium organized by Robarts Research Institute and The University of Western Ontarios Schulich School of Medicine and Dentistry.
19. Jorenby, D. e. et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56-63 (2006).
20. Rigotti, N. A. et al. efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 121, 221-229 (2010).
21. Burt, A. et al. Stopping smoking after myocardial infarction. Lancet 1, 304-306 (1974).
22. Garrow, J. S. Treatment of obesity. Lancet 340, 409-413 (1992).
23. Reimers, C. D., Knapp, G. & Reimers, A. K. Exercise as stroke prophylaxis. Dtsch. Arztebl. Int. 106, 715-721 (2009).
24. Agosti, V., Graziano, S., Artiaco, L. & Sorrentino, G. Biological mechanisms of stroke prevention by physical activity in type 2 diabetes. Acta Neurol. Scand. 119, 213-223 (2009).
25. Strazzullo, P. et al. excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 41, e418-e426 (2010).
26. Dandona, P., Aljada, A. & Bandyopadhyay, A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25, 4-7 (2004).
27. Ghanim, H. et al. Orange juice neutralizes the proinflammatory effect of a high-fat, highcarbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am. J. Clin. Nutr. 91, 940-949 (2010).
28. Dandona, P., Ghanim, H., Chaudhuri, A., Dhindsa, S. & Kim, S. S. Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Exp. Mol. Med. 42, 245-253 (2010).
29. Stunkard, A. J. & Messick, S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J. Psychosom. Res. 29, 71-83 (1985).
30. Heilbronn, L. K. & Ravussin, E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am. J. Clin. Nutr. 78, 361-369 (2003).
31. Fontana, L. & Klein, S. Aging, adiposity, and calorie restriction. JAMA 297, 986-994 (2007).
32. Kagawa, Y. Impact of Westernization on the nutrition of Japanese: changes in physique, cancer, longevity and centenarians. Prev. Med. 7, 205-217 (1978).
33. Sacks, F. M. et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Engl. J. Med. 360, 859-873 (2009).
34. Shai, I. et al. Dietary intervention to reverse carotid atherosclerosis. Circulation 121, 1200-1208 (2010).
35. Spence, J. D., Jenkins, D. J. & Davignon, J. Dietary cholesterol and egg yolks: not for patients at risk of vascular disease. Can. J. Cardiol. (in press).
36. de Lorgeril, M. et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99, 779-785 (1999).
37. Willett, W. C. & Stampfer, M. J. Rebuilding the food pyramid. Sci. Am. 288, 64-71 (2003).
38. Mozaffarian, D., Katan, M. B., Ascherio, A., Stampfer, M. J. & Willett, W. C. Trans fatty acids and cardiovascular disease. N. Engl. J. Med. 354, 1601-1613 (2006).
39. Mozaffarian, D. & Stampfer, M. J. Removing industrial trans fat from foods. BMJ 340, c1826 (2010).
40. Keys, A. Mediterranean diet and public health: personal reflections. Am. J. Clin. Nutr. 61, 1321S-1323S (1995).
41. Shai, I. et al. Weight loss with a lowcarbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229-241 (2008).
42. Graham, I. M. et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 277, 1775-1781 (1997).
43. Nygd, O. et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337, 230-236 (1997).
44. Zhou, J. et al. effects of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoe-deficient mice. Atherosclerosis 168, 255-262 (2003).
45. Bonaa, K. H. et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 354, 1578-1588 (2006).
46. Loscalzo, J. Homocysteine trials-clear outcomes for complex reasons. N. Engl. J. Med. 354, 1629-1632 (2006).
47. Spence, J. D., Bang, H., Chambless, L. E. & Stampfer, M. J. Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 36, 2404-2409 (2005).
48. Lonn, e. et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 354, 1567-1577 (2006).
49. Rajan, S. et al. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J. Am. Geriatr. Soc. 50, 1789-1795 (2002).
50. Spence, J. D. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 7, 830-838 (2007).
51. Poli, D. et al. Culprit factors for the failure of wellconducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 36, 2159-2163 (2005).
52. House, A. A. et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303, 1603-1609 (2010).
53. Urquhart, B. L., Freeman, D. J., Spence, J. D. & House, A. A. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am. J. Kidney Dis. 49, 109-117 (2007).
54. Herrmann, W., Obeid, R., Schorr, H. & Geisel, J. The usefulness of holotranscobalamin in predicting vitamin B12 status in different clinical settings. Curr. Drug Metab. 6, 47-53 (2005).
55. Vogiatzoglou, A. et al. Determinants of plasma methylmalonic acid in a large population: implications for assessment of vitamin B12 status. Clin. Chem. 55, 2198-2206 (2009).
56. Spence, J. D. Nutrition and stroke prevention. Stroke 37, 2430-2435 (2006).
57. Smith, A. D. & Refsum, H. Vitamin B-12 and cognition in the elderly. Am. J. Clin. Nutr. 89, 707S-711S (2009).
58. Wolf-Maier, K. et al. Hypertension treatment and control in five european countries, Canada, and the United States. Hypertension 43, 10-17 (2004).
59. Li, C., Engstrom, G., Hedblad, B., Berglund, G. & Janzon, L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke 36, 725-730 (2005).
60. Spence, J. D. In Hypertension: Pathophysiology, Diagnosis, and Management (eds Laragh, J. H. & Brenner, B.) 741-753 (Raven Press, New York, 1995).
61. Hachinski, V. C. & Norris, J. W. The Acute Stroke 27-40 (F. A. Davis Company, Philadelphia, 1985).
62. Birkett, N. J., Donner, A. P. & Maynard, M. Prevalence and control of hypertension in an Ontario county. Can. Med. Assoc. J. 132, 1019-1024 (1985).
63. Spence, J. D. Antihypertensive drugs and prevention of atherosclerotic stroke. Stroke 17, 808-810 (1986).
64. Bass, M. J., McWhinney, I. R. & Donner, A. Do family physicians need medical assistants to detect and manage hypertension? CMAJ 134, 1247-1255 (1986).
65. Spence, J. D. Physiologic tailoring of therapy for resistant hypertension: 20 years experience with stimulated renin profiling. Am. J. Hypertens. 12, 1077-1083 (1999).
66. Wallach, L., Nyarai, I. & Dawson, K. G. Stimulated renin: a screening test for hypertension. Ann. Intern. Med 82, 27-34 (1975).
67. Wong, D. G., Spence, J. D., Lamki, L. & McDonald, J. W. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1, 997-1001 (1986).
68. Egan, B. M. et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am. J. Hypertens. 22, 792-801 (2009).
69. Spence, J. D. Physiologic tailoring of treatment in resistant hypertension. Curr. Cardiol. Rev. 6, 213-219 (2010).
70. Spence, J. D. Treatment options for renovascular hypertension. Expert Opin. Pharmacother. 3, 411-416 (2002).
71. Howard, G. et al. Racial and geographic differences in awareness, treatment, and control of hypertension: the Reasons for Geographic And Racial Differences in Stroke study. Stroke 37, 1171-1178 (2006).
72. Hachinski, V. et al. Lipids and stroke: a paradox resolved. Arch. Neurol. 53, 303-308 (1996).
73. Amarenco, P. et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med. 355, 549-559 (2006).
74. Sillesen, H. et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 39, 3297-3302 (2008).
75. Kastelein, J. J. et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
76. Spence, J. D. Is carotid intima-media thickness a reliable clinical predictor? Mayo Clin. Proc. 83, 1299-1300 (2008).
77. Spence, J. D. The importance of distinguishing between diffuse carotid intima medial thickening and focal plaque. Can. J. Cardiol. 24, 61C-64C (2008).
78. Finn, A. V., Kolodgie, F. D. & Virmani, R. Correlation between carotid intimal/medial thickness and atherosclerosis. A point of view from pathology. Arterioscler. Thromb. Vasc. Biol. 30, 177-181 (2009).
79. Taylor, A. J. et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J Med. 361, 2113-2122 (2009).
80. Spence, J. D. & Hackam, D. G. Treating arteries instead of risk factors. A paradigm change in management of atherosclerosis. Stroke 41, 1193-1199 (2010).
81. Spence, J. D. et al. Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch. Neurol. 67, 180-186 (2010).
82. Spence, J. D. Adding ezetimibe to statin halts progression of carotid plaque [abstract]. Basic Clin. Pharmacol. Toxicol. 107 (Suppl. 1), 2194 (2010).
83. Tkac, I. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: overview and metaanalysis of five trials. Diabetes Res. Clin. Pract. 86, S57-S62 (2009).
84. Stettler, C. et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am. Heart J. 152, 27-38 (2006).
85. Cushman, W. C. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
86. Wilcox, R. et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular events 04). Stroke 38, 865-873 (2007).
87. Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
88. The Insulin Resistance Intervention after Stroke Trial. Welcome to IRIS, the Insulin Resistance Intervention after Stroke Trial [online], http://www.iristrial.org/(2010).
89. Taylor, D. W. et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid endarterectomy (ACe) Trial Collaborators. Lancet 353, 2179-2184 (1999).
90. Patrono, C. & Baigent, C. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol. Interv. 9, 31-39 (2009).
91. Halkes, P. H., van Gijn, J., Kappelle, L. J., Koudstaal, P. J. & Algra, A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (eSPRIT): randomised controlled trial. Lancet 367, 1665-1673 (2006).
92. [No authors listed] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIe). CAPRIe Steering Committee. Lancet 348, 1329-1339 (1996).
93. Sacco, R. L. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238-1251 (2008).
94. Wong, K. S. et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 9, 489-497 (2010).
95. Fox, K. A. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic events (CURe) Trial. Circulation 110, 1202-1208 (2004).
96. Juurlink, D. N. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180, 713-718 (2009).
97. Schomig, A. Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N. Engl. J. Med. 361, 1108-1111 (2009).
98. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
99. Spence, J. D. Stroke: atrial fibrillation, stroke prevention therapy and aging. Nat. Rev. Cardiol. 6, 448-450 (2009).
100. Tayal, A. H. et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 71, 1696-1701 (2008).
101. Tayal, A. H. & Callans, D. J. Occult atrial fibrillation in ischemic stroke: seek and you shall find. Neurology 74, 1662-1663 (2010).
102. Wallmann, D. et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke 38, 2292-2294 (2007).
103. Ozdemir, A. O., Tamayo, A., Munoz, C., Dias, B. & Spence, J. D. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J. Neurol. Sci. 275, 121-127 (2008).
104. Schwarz, U. I. et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J Med. 358, 999-1008 (2008).
105. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J Med. 361, 1139-1151 (2009).
106. Glaeser, H. et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362-370 (2007).
107. Onalan, O. & Crystal, E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke 38, 624-630 (2007).
108. McPhee, J. T., Schanzer, A., Messina, L. M. & Eslami, M. H. Carotid artery stenting has increased rates of post-procedure stroke, death, and resource utilization than does carotid endarterectomy in the United States, 2005. J. Vasc. Surg. 50, 238-239 (2008).
109. Marquardt, L., Geraghty, O. C., Mehta, Z. & Rothwell, P. M. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. Stroke 41, e11-e17 (2010).
110. Abbott, A. L. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 40, e573-e583 (2009).
111. Rothwell, P. M. Carotid stenting: more risky than endarterectomy and often no better than medical treatment alone. Lancet 375, 957-959 (2010).
112. Brott, T. G. et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N. Engl. J. Med. 363, 11-23 (2010).
113. Markus, H. S. et al. Asymptomatic embolisation for prediction of stroke in the Asymptomatic Carotid emboli Study (ACeS): a prospective observational study. Lancet Neurol. doi:10.1016/S1474-4422(10)70120-4.
114. Silvestrini, M. et al. Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis. JAMA 283, 2122-2127 (2000).
115. Kwee, R. M. et al. Identifying vulnerable carotid plaques by noninvasive imaging. Neurology 70, 2401-2409 (2008).
116. Kakkos, S. K. et al. Silent embolic infarcts on computed tomography brain scans and risk of ipsilateral hemispheric events in patients with asymptomatic internal carotid artery stenosis. J. Vasc. Surg. 49, 902-909 (2009).
117. Giannoukas, A. D., Sfyroeras, G. S., Griffin, M., Saleptsis, V. & Nicolaides, A. N. Association of plaque echostructure and cardiovascular risk factors with symptomatic carotid artery disease. J. Cardiovasc. Surg. (Torino) 51, 245-251 (2010).